These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33843673)

  • 1. Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
    Halminen O; Vesikansa A; Mehtälä J; Hörhammer I; Mikkola T; Virta LJ; Ylisaukko-Oja T; Linna M
    J Alzheimers Dis; 2021; 81(3):1103-1115. PubMed ID: 33843673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.
    Linna M; Vuoti S; Silander K; Hörhammer I; Halminen O; Mikkola T; Koivuranta-Vaara P; Virta LJ; Koivusalo M; Ylisaukko-Oja T
    J Alzheimers Dis; 2019; 71(4):1297-1308. PubMed ID: 31524158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
    Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
    Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
    Barthold D; Joyce G; Ferido P; Drabo EF; Marcum ZA; Gray SL; Zissimopoulos J
    J Alzheimers Dis; 2020; 76(2):579-589. PubMed ID: 32538845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based study of dosing and persistence with anti-dementia medications.
    Brewer L; Bennett K; McGreevy C; Williams D
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1467-75. PubMed ID: 23443628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
    Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
    Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
    Byun J; Lee DY; Jeong CW; Kim Y; Rhee HY; Moon KW; Heo J; Hong Y; Kim WJ; Nam SJ; Choi HS; Park JI; Chun IK; Bak SH; Lee K; Byeon GH; Kim KL; Kim JA; Park YJ; Kim JH; Lee EJ; Lee SA; Kwon SO; Park SW; Kasani PH; Kim JK; Kim Y; Kim S; Jang JW
    Sci Rep; 2022 Mar; 12(1):4451. PubMed ID: 35292697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.
    Lampela P; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
    J Alzheimers Dis; 2020; 73(3):1243-1251. PubMed ID: 31929157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study.
    Vesikansa A; Halminen O; Mehtälä J; Hörhammer I; Mikkola T; Ylisaukko-Oja T; Linna M
    Eur J Health Econ; 2023 Dec; 24(9):1421-1428. PubMed ID: 36449133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
    Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.